Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bimba F Hoyer

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Annals of the Rheumatic Diseases|February 25, 2015
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusTobias Alexander, Ramona Sarfert, Jens Klotsche, et al.
RMD Open|December 9, 2021
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapiesUlf M Geisen, Melike Sümbül, Florian Tran, et al.
BMC Rheumatology|July 31, 2021
The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitisChristof Iking-Konert, Pia Wallmeier, Sabrina Arnold, et al.
Journal of Medical Virology|December 19, 2023
Limited antibody response after BA.4-5 adapted booster vaccination in rheumatic patients receiving anti-TNF therapy: Results of a case seriesUlf M Geisen, Mathias Voß, Ruben Rose, et al.
Annals of the Rheumatic Diseases|March 25, 2021
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohortUlf M Geisen, Dennis K Berner, Florian Tran, et al.
Allergy|July 25, 2024
Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccinationJana Sophia Buhre, Tamas Pongracz, Ulf Martin Geisen, et al.
ERJ Open Research|December 28, 2022
Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19Florian Tran, Danielle M M Harris, Alena Scharmacher, et al.
Frontiers in Medicine|March 21, 2024
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registriesRebecca Hasseli, Frank Hanses, Melanie Stecher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 22, 2021
SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-AnalysisRichard Conway, Alyssa A Grimshaw, Maximilian F Konig, et al.
RMD Open|September 8, 2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine SurveySebastian Eduardo Sattui, Jean W Liew, Kevin Kennedy, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Annals of the Rheumatic Diseases|February 25, 2015
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusTobias Alexander, Ramona Sarfert, Jens Klotsche, et al.
RMD Open|December 9, 2021
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapiesUlf M Geisen, Melike Sümbül, Florian Tran, et al.
BMC Rheumatology|July 31, 2021
The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitisChristof Iking-Konert, Pia Wallmeier, Sabrina Arnold, et al.
Journal of Medical Virology|December 19, 2023
Limited antibody response after BA.4-5 adapted booster vaccination in rheumatic patients receiving anti-TNF therapy: Results of a case seriesUlf M Geisen, Mathias Voß, Ruben Rose, et al.
Annals of the Rheumatic Diseases|March 25, 2021
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohortUlf M Geisen, Dennis K Berner, Florian Tran, et al.
Allergy|July 25, 2024
Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccinationJana Sophia Buhre, Tamas Pongracz, Ulf Martin Geisen, et al.
ERJ Open Research|December 28, 2022
Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19Florian Tran, Danielle M M Harris, Alena Scharmacher, et al.
Frontiers in Medicine|March 21, 2024
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registriesRebecca Hasseli, Frank Hanses, Melanie Stecher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 22, 2021
SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-AnalysisRichard Conway, Alyssa A Grimshaw, Maximilian F Konig, et al.
RMD Open|September 8, 2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine SurveySebastian Eduardo Sattui, Jean W Liew, Kevin Kennedy, et al.
Pageof 5